These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 38250851)

  • 1. Enhancing TB Vaccine Efficacy: Current Progress on Vaccines, Adjuvants and Immunization Strategies.
    Wang H; Wang S; Fang R; Li X; Xing J; Li Z; Song N
    Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38250851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical research concepts in tuberculosis vaccine development.
    Delogu G; Manganelli R; Brennan MJ
    Clin Microbiol Infect; 2014 May; 20 Suppl 5():59-65. PubMed ID: 24283256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis vaccines: beyond bacille Calmette-Guerin.
    McShane H
    Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2782-9. PubMed ID: 21893541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal bovine β-defensin-5 enhances antituberculosis immunity in a mouse model by a novel protein-based respiratory mucosal vaccine.
    Liang Z; Li H; Qu M; Liu Y; Wang Y; Wang H; Dong Y; Chen Y; Ge X; Zhou X
    Virulence; 2022 Dec; 13(1):949-962. PubMed ID: 35603910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of Th1-Type Immune Responses to
    Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG
    J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization strategies against pulmonary tuberculosis: considerations of T cell geography.
    Horvath CN; Xing Z
    Adv Exp Med Biol; 2013; 783():267-78. PubMed ID: 23468114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity.
    Stewart E; Triccas JA; Petrovsky N
    Microorganisms; 2019 Aug; 7(8):. PubMed ID: 31409028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing New Anti-Tuberculosis Vaccines: Focus on Adjuvants.
    Franco AR; Peri F
    Cells; 2021 Jan; 10(1):. PubMed ID: 33466444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are chitosan natural polymers suitable as adjuvant/delivery system for anti-tuberculosis vaccines?
    Khademi F; Taheri RA; Yousefi Avarvand A; Vaez H; Momtazi-Borojeni AA; Soleimanpour S
    Microb Pathog; 2018 Aug; 121():218-223. PubMed ID: 29800697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in protein subunit vaccines against tuberculosis.
    Zhang Y; Xu JC; Hu ZD; Fan XY
    Front Immunol; 2023; 14():1238586. PubMed ID: 37654500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural and trained innate immunity against Mycobacterium tuberculosis.
    Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U
    Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices.
    MMWR Recomm Rep; 1996 Apr; 45(RR-4):1-18. PubMed ID: 8602127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
    Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
    Front Immunol; 2020; 11():575504. PubMed ID: 33117374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel vaccination strategies and approaches against human tuberculosis.
    Méndez-Samperio P
    Scand J Immunol; 2019 Aug; 90(2):e12774. PubMed ID: 31054193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current challenges and opportunities for bacillus Calmette-Guérin replacement vaccine candidates.
    Méndez-Samperio P
    Scand J Immunol; 2019 Oct; 90(4):e12772. PubMed ID: 31055842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
    Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
    PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of Cationic Liposomes as Adjuvants/Delivery Systems for Tuberculosis Subunit Vaccines.
    Khademi F; Taheri RA; Momtazi-Borojeni AA; Farnoosh G; Johnston TP; Sahebkar A
    Rev Physiol Biochem Pharmacol; 2018; 175():47-69. PubMed ID: 29700609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis vaccines: Opportunities and challenges.
    Zhu B; Dockrell HM; Ottenhoff THM; Evans TG; Zhang Y
    Respirology; 2018 Apr; 23(4):359-368. PubMed ID: 29341430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ag85b/ESAT6-CFP10 adjuvanted with aluminum/poly-IC effectively protects guinea pigs from latent mycobacterium tuberculosis infection.
    Wang C; Lu J; Du W; Wang G; Li X; Shen X; Su C; Yang L; Chen B; Wang J; Xu M
    Vaccine; 2019 Jul; 37(32):4477-4484. PubMed ID: 31266673
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.